The COVID-19 news world saw a return of Monday-morning vaccine results this week. Novavax, a small biotech company based in Maryland, announced that its vaccine demonstrated 90% overall efficacy and 100% protection against moderate and severe COVID-19 disease.
These results come from a trial conducted in the U.S. and Mexico between January and April this year, at a time when the Alpha (or B.1.1.7) variant was becoming dominant here. Among almost 30,000 trial participants, 77 cases were observed: 63 in the placebo group and 14 in the vaccine group, for an efficacy of 90.4%. All of the moderate and severe cases (ten moderate, four severe) were observed in the placebo group.
Novavax even sequenced samples from 54 out of the 77 cases. The majority of those sequenced cases were variants of concern or variants of interest; Novavax’s vaccine demonstrated 93.2% efficacy against variants of concern/interest and 100% efficacy against non-concerning variants. This finding aligns with other vaccine studies suggesting that the COVID-19 vaccines developed on older versions of the virus still work well against variants, especially at protecting against severe disease and death.
This new vaccine uses a coronavirus protein—a different method from both Moderna/Pfizer (mRNA vaccines) and AstraZeneca/Johnson & Johnson (adenovirus vaccines). It’s given in two doses, three weeks apart. It had far fewer side effects than other COVID-19 vaccines, with small numbers of participants reporting sore arms and fatigue.
The Novavax vaccine is also comparatively easier to transport and store than other viruses; it can be stored at refrigerated temperatures. While it’s unlikely to be used in the U.S., it could be critical for vaccine rollouts in other parts of the world.
More vaccine data
- The booster shot conversation: What you should knowRecently, a lot of U.S. COVID-19 news has centered around booster shots—additional vaccine doses to boost patients’ immunity against the coronavirus. Questions abound: do we need these shots, when might we need them, how do they impact vaccination campaigns?
- What’s up with Texas’ county-level vaccination data?Anyone who’s tried to work with the federal government’s vaccination data has noticed this issue: there’s a Texas-shaped hole in the numbers. While the CDC and HHS report vaccination data for counties and metropolitan areas in the vast majority of states, data are missing for the entire state of Texas.
- Breakthrough cases: What we know right nowWhile epidemiologists may consider any new outbreak a possible source of new variants, one key way to monitor the virus/variant race is by analyzing breakthrough cases—those infections that occur after someone has been fully vaccinated. Here’s how states and the CDC are tracking these cases now, and what we know about vaccine protection against the variants.
- The US missed Biden’s July 4 goal: How did your community do?The U.S. missed President Biden’s big vaccination goal: 70% of adults vaccinated with at least one dose by July 4. As of July 3, we are at 67% of adults with one dose, and 58% fully vaccinated. But rates vary widely by state and county: There are over 1,000 counties in the U.S. with one-dose vaccination rates under 30%, CDC Director Dr. Walensky said at a press briefing last week.
- Novavax vaccine performs well—including against variantsThe COVID-19 news world saw a return of Monday-morning vaccine results this week. Novavax, a small biotech company based in Maryland, announced that its vaccine demonstrated 90% overall efficacy and 100% protection against moderate and severe COVID-19 disease.